Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study
No Thumbnail Available
Authors
Monk, B. J.
Ghatage, P.
Parekh, T.
Henitz, E.
Knoblauch, R.
Matos-Pita, A. S.
Nieto, A.
Park, Y. C.
Cheng, P. S.
Li, W.
Issue Date
2015
Type
Journal Article
Language
eng_US
Keywords
Alternative Title
Abstract
Description
Citation
Monk, B. J.; Ghatage, P.; Parekh, T.; Henitz, E.; Knoblauch, R.; Matos-Pita, A. S.; Nieto, A., et al. (2015). Effect of BRCA1 and XPG Mutations on Treatment Response to Trabectedin and Pegylated Liposomal Doxorubicin in Patients with Advanced Ovarian Cancer: Exploratory Analysis of the Phase 3 OVA-301 Study. Annals of Oncology : Official Journal of the European Society for Medical Oncology / ESMO, 2015 May, 26(5):914-920. doi: http://doi.org/10.1093/annonc/mdv071
Publisher
. Published by Oxford University Press on behalf of the European Society for Medical Oncology
License
Journal
Volume
Issue
PubMed ID
DOI
ISSN
1569-8041
0923-7534
0923-7534